Q-omics provides the consensus-scored PIK3CG profile across patient tissues and cancer cell-line models. PIK3CG expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PIK3CG is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PIK3CG RNA expression shows 22,733 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where PIK3CG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIK3CG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIK3CG survival associations across molecular data types. PIK3CG RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIK3CG RNA expression–survival associations across cancer types. High PIK3CG expression shows unfavorable associations in LGG, but favorable associations in HNSC, LUAD, SKCM, KIRC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PIK3CG RNA expression.
This table summarizes PIK3CG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PIK3CG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIK3CG shows lower tumor expression in COAD, LUSC, UCEC and KICH and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher PIK3CG RNA expression in tumor versus normal tissue (log2 FC = +1.265, t-test p < 0.001).
This table shows molecular features associated with PIK3CG in patient tissues and cancer cell lines. In patient samples, PIK3CG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PIK3CG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
